The Need: With more than 5,000 clinical trials related to gene therapy, there is significant need for devices that enhance efficacy of these therapies. This is evident by the more than 70 clinical trials for direct-contact electroporation devices.
The Solution: SIDD is a non-contact platform device designed to enhance delivery for a broad spectrum of therapeutics such as plasmid DNA, antisense oligonucleotides, siRNA, and proteins. The device uses a stream of electrical charge that causes cells/tissues to uptake target molecules. The device has been shown to be as or more effective than conventional direct-contact electroporation devices in side by side testing. Preclinical tests show efficacy for enhanced DNA vaccine delivery and gene electrotransfer for cancer treatment. These preclinical studies also show that the technology has an excellent safety profile